Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support

Contributed by: Business Wire

Logo

Tags

Professional Services

Health

Start-Up

Finance

Pharmaceutical

Biotechnology

Sofinnova Partners

More Like This

Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups

Sofinnova Partners Raises €1.2 Billion to Fuel the Next Wave of Life Sciences Innovation

Edward Kliphuis, Partner, Sofinnova Digital Medicine Strategy and Simon Turner, Partner, Sofinnova Digital Medicine Strategy (Photo: Sofinnova Partners)

Sofinnova Partners Raises $200M Digital Medicine Fund

Sofinnova Partners and Gustave Roussy forge strategic alliance to boost oncology startup acceleration in France

Sofinnova.AI (Photo: Sofinnova)

Sofinnova Partners Unveils Sofinnova.AI: A Cutting-edge Artificial Intelligence Platform Set to Transform Its Life Sciences Investment Practice

Sofinnova Partners Enhances Leadership in Medtech Acceleration with Key Appointments

Sofinnova Partners Appoints Two New Partners Strengthening Team of Next Generation Investors

Sofinnova Partners Brings in Dr. Joshua Makower, Stanford Biodesign Co-Founder, as Venture Partner